Myocardial Infarction Global Market By Type, By Application, By Distribution Channel, By End User, By Region And Segment Forecast 2024-2033 | Bayer AG, Novartis AG, Sanofi SA, AstraZeneca PLC, Abbott Laboratories

Spread the love

The Myocardial Infarction Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Myocardial Infarction Market:
https://www.thebusinessresearchcompany.com/report/myocardial-infarction-global-market-report

According to The Business Research Company’s Myocardial Infarction Global Market Report 2024, The myocardial infarction market size has grown strongly in recent years. It will grow from $1.9 billion in 2023 to $2.04 billion in 2024 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to introduction of beta-blockers, establishment of chest pain centers, thrombolytic therapies, enomic and personalized medicine approaches, wearable cardiovascular devices.

The myocardial infarction market size is expected to see strong growth in the next few years. It will grow to $2.68 billion in 2028 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to global health initiatives for cardiovascular health, expanded access to reperfusion therapies, rna therapeutics for cardiovascular diseases, patient-centered care models, focus on microvascular dysfunction, bioelectronic medicine. Major trends in the forecast period include advancements in cardiovascular imaging, advancements in cardiac surgery techniques, advancements in telemedicine, integration of artificial intelligence in diagnosis, innovation of digital biomarkers for risk prediction, blockchain for healthcare data security, ai-driven drug discovery, innovations in cardiac rehabilitation technologies.

An increasing number of smokers is expected to propel the growth of the myocardial infarction market going forward. A smoker is anyone who smokes cigarettes, cigars, or a pipe. Cigarette smoke contains chemicals that cause the blood to thicken and clot in veins and arteries, and a blockage brought on by a clot can result in myocardial infarction. For instance, in September 2023, according to the Office for National Statistics, a UK-based government department, the segment of the UK population aged 25 to 34 years maintained the highest percentage of current smokers, accounting for 16.3% or approximately 1.4 million individuals in 2022. This represents an increase from the previous year, when the same age group had a smoking prevalence of 15.8%, encompassing around 1.3 million people. Therefore, an increasing number of smokers is driving the growth of the myocardial infarction market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=12164&type=smp

The myocardial infarction market covered in this report is segmented –
1) By Drug Class: Antiplatelet Agents, Glycoprotein IIb/IIIa Inhibitors, Antithrombotic Agents, Beta-adrenergic Blockers, Vasodilators, Angiotensin-converting Enzyme (ACE) Inhibitors, Angiotensin-receptor Blockers, Analgesics, Thrombolytics
2) By Route Of Administration: Oral, Injectable
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Major companies in the myocardial infarction market are focused on developing novel drugs, such as anti-inflammatory drugs, for targeted cardiovascular inflammation treatment and to gain a competitive edge in the market. Anti-inflammatory drugs are medications that reduce inflammation, alleviating pain and swelling by targeting the body’s immune response. For instance, in June 2023, Agepha Pharma, a Slovakia-based manufacturer of medical products, received FDA approval for its developed drug, Lodoco (colchicine), the first anti-inflammatory drug to target the underlying cause of atherosclerotic cardiovascular disease. Lodoco aims to reduce the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in adult patients. It can be used alone or with cholesterol-lowering medications. Lodoco, a reformulated low-dose colchicine, demonstrated a 31% reduction in the overall risk of cardiovascular death, myocardial infarction, stroke, or coronary revascularization in a clinical trial.

The myocardial infarction market report table of contents includes:
1. Executive Summary